LifeVantage (LFVN) Earning Somewhat Favorable Media Coverage, Accern Reports
News coverage about LifeVantage (NASDAQ:LFVN) has trended somewhat positive on Sunday, Accern reports. The research group identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. LifeVantage earned a news impact score of 0.03 on Accern’s scale. Accern also gave media headlines about the company an impact score of 46.3655492930831 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
LifeVantage traded up $0.57, hitting $11.33, on Friday, Marketbeat.com reports. The company had a trading volume of 307,700 shares, compared to its average volume of 252,010. The company has a market cap of $152.90 million, a price-to-earnings ratio of 41.96 and a beta of 0.75. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.53 and a quick ratio of 0.91. LifeVantage has a 52 week low of $2.86 and a 52 week high of $11.40.
LifeVantage (NASDAQ:LFVN) last issued its quarterly earnings data on Wednesday, May 9th. The company reported $0.12 EPS for the quarter. The business had revenue of $50.56 million during the quarter. LifeVantage had a net margin of 1.43% and a return on equity of 29.72%. analysts expect that LifeVantage will post 0.47 EPS for the current year.
LifeVantage Corporation identifies, researches, develops, and distributes nutraceutical dietary supplements and skin care products. It offers Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skin care product; Axio energy drink mixes; and PhysIQ, a weight management system, as well as Petandim for Dogs, a companion pet supplement formulated to combat oxidative stress in dogs.
See Also: NASDAQ Stock Market Explained
Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with MarketBeat.com's FREE daily email newsletter.